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Abstract
Coordinated bone growth is controlled by numerous mechanisms which are only partially understood because of the
involvement of many hormones and local regulators. The C-type Natriuretic Peptide (CNP), encoded by NPPC gene located
on chromosome 2q37.1, is a molecule that regulates endochondral ossification of the cartilaginous growth plate and
influences longitudinal bone growth. Two independent studies have described three patients with a Marfan-like phenotype
presenting a de novo balanced translocation involving the same chromosomal region 2q37.1 and overexpression of NPPC.
We report on two partially overlapping interstitial 2q37 deletions identified by array CGH. The two patients showed
opposite phenotypes characterized by short stature and skeletal overgrowth, respectively. The patient with short stature
presented a 2q37 deletion causing the loss of one copy of the NPPC gene and the truncation of the DIS3L2 gene with
normal CNP plasma concentration. The deletion identified in the patient with a Marfan-like phenotype interrupted the
DIS3L2 gene without involving the NPPC gene. In addition, a strongly elevated CNP plasma concentration was found in this
patient. A possible role of NPPC as causative of the two opposite phenotypes is discussed in this study.
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Introduction
During embryonic development and in postnatal life, longitu-
dinal bone growth occurs at the cartilaginous growth plates located
at the ends of the vertebrae and long bones. This process involves
systemic hormones and local regulators that are finely tuned to
allow harmonious and coordinated bone growth. Among these,
CNP (C-type natriuretic peptide) plays an essential role in
regulating bone growth by influencing cartilage homeostasis,
proliferation and differentiation of osteoblasts and osteoclasts, and
endochondral bone growth [1–4]. It is encoded by the NPPC gene
located on chromosome 2q37.1 and exerts its effect through the
interaction with the natriuretic peptide receptor B (NPR2 or
NPRB) [5]. Knock-out mice for the CNP coding gene showed
marked dwarfism due to impaired endochondral ossification [6–
8].Targeted expression of CNP in chondrocytes rescued the
dwarfism of CNP deficient mice, indicating that CNP acts as a
local regulator of longitudinal bone growth [7]. Up to now no
mutation or loss of the NPPC gene associated with dwarfism has
been reported in humans. Homozygous mutations of the NPR2
gene have been identified in patients affected by acromesomelic
dysplasia or Maroteaux type (MIM 602875), while heterozygous
mutations of the same receptor gene have been associated with
short stature [9–10]. Conversely, overexpression of the NPPC gene
determines skeletal overgrowth in transgenic mice [3] and in
humans [11–13]. A recent genome-wide association study
suggested that variation in the CNP signaling pathway, involving
the NPPC and NPR3 genes, plays an important role in determining
human body height [14].
We report on two different patients with de novo 2q37 deletions.
Patient 1 is affected by a pathological short stature and presents a
2q37.1 deletion of 1.9 Mb, while Patient 2 has a 2q37.1q37.3
deletion of 4.5 Mb associated with a Marfan-like phenotype. We
discuss the possible role of NPPC in determining the two opposite
phenotypes.
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Results
Clinical Report
Patient 1. The patient, a 7 year-old-girl, is the second child of
healthy non-consanguineous parents; parents’ height was normal
(father’s height was 180,8 cm and mother’s height 157,4 cm). In
the family, a maternal first cousin had severe mental delay with
abnormal behaviour and a paternal granduncle showed bilateral
upper limb malformation. The patient has a healthy 9-year-old
sister. Ultrasound examination revealed intrauterine growth
retardation and polyhydramnios. The patient was born at
37 weeks of gestation by spontaneous delivery.
Birth weight was 2275 g (,3th centile), length 42 cm (,3th
centile) and the occipitofrontal circumference (OFC) 34.5 cm (75th
centile); Apgar score was 9 and 10 at 1 and 5 minutes, respectively.
At the age of 20 months, growth parameters were weight 7620 g
(,3th centile), height 73 cm (,3th centile), OFC 46.5 cm (50th–
75th centile). Clinical examination showed facial dysmorphisms
including pyriform skull with prominent forehead, upward slanting
eyebrows, strabismus, epicanthus, low-set ears, depressed nasal
bridge, short philtrum, V-shaped mouth and short upper lip. Feet
showed mild brachydactyly, cutaneous syndactyly of 2nd and 3rd
toes bilaterally, axial and limb girdle hypotonia, mild lower limb
dysmetria (left.right), joint laxity. Growth has always been quite
poor. At 6 years 5 months height was 103.4 cm (3th centile).
Psychomotor and language development were delayed. Ophthal-
mological examination showed refractive errors and, at the age of
two months, peripheral hearing loss was confirmed by auditory
brainstem response (ABR test). Chest X-ray revealed 13 rib pairs
and brain MRI showed a corpus callosum dysgenesis. Echocar-
diogram showed mild mitral valve insufficiency. Arginine stimu-
lation test showed a normal GH response, thus ruling out GH
deficiency. Photographs of the patient is shown in Figure 1.
Patient 2. The patient is a 12-year-old boy born to non-
consanguineous parents. No family history of congenital anomalies
or mental retardation was reported. He has a healthy 4 year-old
sister. The patient was born at full term after an uneventful
pregnancy by spontaneous vaginal delivery. Exposure to drugs or
infection during the pregnancy was denied. At birth, weight was
3.300 kg (25th–50th centile), length 54 cm (90–95th centile) and
occipitofrontal circumference (OFC) 34 cm (10th–25th centile).
Psychomotor development was normal. At the age of 12 years,
weight was 30 kg (5th centile), height 165 cm (.97th centile) and
OFC 53.7 cm (.50th centile). Marfanoid habitus, arachnodactyly
of hands and feet with very long hallux bilaterally associated and
mild syndactyly of 3rd, 4th and 5th fingers, and severe scoliosis were
observed (Fig. 2). Echocardiography showed patent ductus
arteriosus.
Figure 1. Clinical signs of the patient 1. The patient 1 at 3 years of
age: short stature, prominent forehead, strabismus, epicanthus, low-set-
ears, depressed nasal bridge, short phyltrum, V-shaped mouth. Mild
brachydactyly, cutaneous syndactyly of 2nd and 3rd toes.
doi:10.1371/journal.pone.0066048.g001
Figure 2. Clinical signs of the patient 2. A) Details of feet, showing
very long hallux bilaterally B) X-rays, showing severe scoliosis. C) Long
and curved lower limbs.
doi:10.1371/journal.pone.0066048.g002
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Cytogenetic and Array-CGH Analysis
Cytogenetic analysis, performed on GTG-banded metaphases
from cultured lymphocytes of both patients and their parents
showed normal karyotypes. Considering the phenotypic abnor-
malities of the patients, array CGH analysis (Agilent G3 400 K)
was performed.
In patient 1 array CGH analysis revealed a de novo interstitial
deletion of ,1.9 Mb at 2q37.1 band (chr2:231,264,596–
233,178,325 )61 (Fig. 3, A). The presence of the deletion was
confirmed by FISH with BAC clone RP11-395A23 (AC010149)
(Fig. 3, B).
At least 20 annotated genes were included within the deleted
region. Among those genes, the NPPC gene had been previously
associated with overgrowth and skeletal anomalies [11–13]. The
deletion also leads to the truncation of DIS3L2 locus in the intronic
region comprised between exons 14 and 15 (Fig. 4).
In patient 2, a de novo interstitial 2q37.1q37.3 deletion of
,4.5 Mb (chr2:232,963,736 -237,479,062)61 was identified by
array CGH (Fig. 3, C). The deletion was confirmed by FISH with
BAC clone RP11-485M18 (AC079400)(Fig 3, D). The deleted
region contained 45 annotated genes and its proximal (centro-
meric) breakpoint interrupted the DIS3L2 gene in intron 6 (Fig 4).
The two rearrangements shared an overlapping region of
214 kb containing 8 exons of DIS3L2 locus (from exon 7 to exon
14) and a gene coding for hsa-miR-562 (Fig 4). The microRNA
sequence was within intron 9 of DIS3L2 and it was deleted in both
patients. No additional imbalance was detected in patients 1 and 2.
Gene expression analysis
CNP concentration was measured in plasma samples from the
two patients, their parents and six female and six male volunteers.
For each family member, two double determinations were
performed and, for controls, only one double determination.
CNP-22 plasma concentration was significantly elevated in patient
2 compared to controls as showed in Fig. 5, A. In this patient, the
increased plasmatic levels of CNP were correlated with overex-
pression of the corresponding gene at mRNA level, as assessed by
RT-qPCR (Fig 5, B). Conversely, patient 1 showed normal CNP-
22 concentration and normal expression of NPPC mRNA, despite
complete deletion of one copy of the gene (Fig. 6). The presence of
mutations in the promoter region and in the coding sequence of
NPPC was excluded for both patients (data not shown).
Figure 3. Array-CGH and FISH results. A) Result of array-CGH analysis of chromosome 2 with Agilent Human Genome CGH microarray Kit G3 400
in patient 1. The 1.914 Mb interstitial q37.1 deleted region of chromosome 2 extends between oligomers A_18_P13670199 (231,264,956 bp) and
A_16_P00618306 (233,178,325 bp) flanked by oligomers A_16_P00615757 (231,257,468 bp) and A_16_P00618312 (233,181,399 bp) (UCSC Genome
Browser, http://genome.ucsc.edu/; February 2009). B) FISH with BAC clones RP11-395A23 (AC010149) (chr2:231,304,236–231,476,367). The arrowhead
indicates the deleted chromosome 2. D) Result of array-CGH analysis of chromosome 2 with Agilent Human Genome CGH microarray Kit G3 400 in
patient 2. The 4.515 Mb interstitial deletion at bands q37.1q37.3 of chromosome 2 was comprised between oligomers A_16_P16076619
(232,963,736 bp) and A_16_P36124457(237,479,062 bp) flanked by oligomers A_16_P16076610 (232,954,321 bp) and A_16_P36124475
(237,483,914 bp). C) FISH with RP11-485M18 (AC079400)(chr2:236,766,818-236,919,215). The arrowhead shows the deleted chromosome 2.
doi:10.1371/journal.pone.0066048.g003
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Discussion
The control mechanisms that allow for coordinated bone
growth throughout the body are only partially understood, due to
the involvement of many systemic hormones and local regulators.
The NPPC gene codes for CNP, a molecule that regulates
endochondral ossification of the cartilaginous growth plate and,
hence, influences longitudinal bone growth. The CNP/NPR2
system has only recently proved to be an important regulator of
human growth. Overexpression of NPPC has been shown to cause
skeletal overgrowth. On the contrary, disruption of Nppc or Npr-2
genes proved to lead to dwarfism and severe skeletal malforma-
tions in mice [7–8].
Moreover, two independent studies have described three
patients characterized by postnatal skeletal overgrowth, Marfanoid
habitus, arachnodactyly with abnormally long halluces, and
marked overgrowth of the long bones, carrying de novo balanced
translocations involving the same chromosomal region in 2q37
and three different chromosome partners [11–12]. The three
breakpoints mapped around the 59 end of the DIS3L2 gene (Fig. 4),
however this locus was not considered as a candidate.
Recently, germline homozygous mutations in DIS3L2 have been
associated with Perlman syndrome, a rare overgrowth and cancer
susceptibility disorder [15–16]. However, considering its wide
expression, the DIS3L2 gene does not represent a convincing
candidate for a bone affecting phenotype.
The peculiar skeletal phenotype of the translocated patients has
been found to an up-regulation of the NPPC gene both at mRNA
and at circulating peptide level [11–12]. As the gene was not
disrupted by the translocations nor mutated in the proximal
promoter region or in the coding sequence, it was assumed that
rearrangements caused a separation of the NPPC gene unit from a
negative, cis-acting, long-distance regulatory sequence.
Interestingly, a genome-wide association study on northwestern
Europeans found that genetic variants close to the NPPC gene
were significantly linked with body height [14].
Here we report on two patients with a deletion in 2q37 locus
identified by array CGH.
Patient 1 showed short stature, cranial asymmetry, moderate
psychomotor delay, and a de novo 2q37.1 interstitial deletion
encompassing many genes including NPPC and the first 14 exons
of DIS3L2. NPPC expression and CNP circulating peptide levels
were normal.
Mice with targeted disruption of CNP (Nppc–/–) displayed
striking narrowing of the growth plate of vertebrae and long bones
compared to wild type mice and showed severe dwarfism as a
result of impaired endochondral ossification [7]. Similarly, the
‘‘long bone abnormality’’ (lbab/lbab) mice, mutants due to a
spontaneous autosomal recessive hypomorphic mutation in the
Nppc gene, developed severe dwarfism characterized by short tails
and extremities, while heterozygous mice did not differ from wild-
type mice. These studies confirmed that haploinsufficiency of the
NPPC gene does not exist in mice [17]. On the contrary, the effects
of haploinsufficiency of this gene are evident in humans which
could be due to differences between species or some other
unknown mechanism(s). CNP is especially crucial for skeletal
growth spurt that occurs in early life, is expressed in the growth
plate cartilage, and works as an autocrine/paracrine regulator
[17]. In the study by Moncla et al. [12], the NPPC gene was not
expressed in normal lymphoblasts under normal conditions while
it is expressed 6-fold in chondrocytes of his patient P1. We think
that ‘‘normal’’ expression of NPPC in our patient 1was due to a
mild overexpression of the unique gene copy and it could
interpreted as an attempt to functional recovery.
The second patient of our study is a 12-year-old boy with
marfanoid habitus associated with arachnodactyly of hands and
feet, mild syndactyly, and severe scoliosis. He is affected by an
interstitial 2q37.1q37.3 deletion of 4.5 Mb leading to overexpres-
sion of the NPPC gene. The deletion disrupts the DIS3L2 gene at
the level of exon 6. The phenotype is very similar to that of the
other three patients previously described [11–12]. Interestingly, in
two cases (patient 2, reported by Bocciardi [11] and patient 2
reported by Moncla [12]), the breakpoints were located into the
Figure 4. Schematic representation of the genomic region spanning the described deletions according to the UCSC Genome
Browser Feb 2009 (GRCh37/hg19). Several annotated genes and ESTs are present, the two deletions are indicated by black arrows (patient 1 and
patient 2), whereas triangles indicate the position of the translocation breakpoints previously published [11–12].
doi:10.1371/journal.pone.0066048.g004
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DIS3L2 gene, while in patient 1 described by Moncla et al. [12]
the translocation breakpoint was about 18 Kb centromeric to
DIS3L2.
The overlapping region of 214 kb shared by the two deletions
contained an additional gene coding for a microRNA named hsa-
miR-562 which is expressed only in kidney and colon and
regulates EYA1, a critical gene for renal development. The
haploinsufficiency of miR-562 contributes to the etiology of Wilms
tumor by promoting deregulation of EYA1 [18].Considering the
putative role of miR-562 in sporadic Wilms tumor and its specific
expression pattern, we couldn’t speculate a possible role of this
microRNA in determining the phenotypes observed in our
patients.
About the other genes present in the two deletions, we could
retain that the ones included in patient 1 deletion may have caused
the additional dysmorphisms other than the bone phenotype,
while the 45 genes in patient 2 deletion appear to have had no
significant effects on the phenotype.
To our knowledge, this is the first report of NPPC heterozygous
deletion associated with short stature. The description of a second
case (patient 2) with an opposite phenotype confirms a correlation
between the loss of long range control elements which regulate
NPPC functional activity and skeletal overgrowth. Moreover, these
results highlight the possibility of identifying novel therapeutic
strategies for the treatment of dwarfism or skeletal overgrowth.
Materials and Methods
Ethics Statement
The current study was performed using peripheral blood of the
members of the two families treated at the Istituto Giannina
Gaslini, Genova, Italy. The parents of the patients gave written
informed consent allowing molecular and genetic studies. We
didn’t request approval by Review Board of our institution,
because our study request only classical and molecular cytogenetic
analyses. For cytogenetics analyses are sufficient only written
informed consent of the parents (DM 21 dicembre 2007). The
informed consents of the parents were previously authorized by
the Review Board of our institution. We didn’t conduct research
outside our country of residence. We didn’t approach the local
authorities before beginning work on this study. The full name of
the ethics committee of our institution is Comitato di Etica per la
Ricerca Scientifica Biomedica, per la Buona Pratica Clinica e per
la Sperimentazione dei Farmaci. The parents of the two patients
allowed us to publish the descriptive details of their children’s
malformations.
The parents of the individuals in this manuscript have given
written informed consent (as outlined in PLOS consent form) to
publish these case details.
Clinical material
The current study was performed using peripheral blood of the
members of the two families treated at the Istituto Giannina
Gaslini, Genova, Italy.
Cytogenetic, array-CGH and fluorescence in situ
hybridization analyses. Cytogenetic analysis was performed
on GTG-banded metaphases at a resolution of 400–550 bands.
Chromosome preparations were made from cultured lymphocytes
of patients and their parents.
Fluorescence in situ hybridization (FISH) analysis performed
using conventional protocols. BAC clones were selected from the
human library RPCI-11 according to the UCSC Genome Browser
(http://genome.ucsc.edu/; GRCh37/hg19, February 2009). BAC
probes were directly labeled with Spectrum-Orange by nick
translation (Vysis/Abbott, Downers Grove, IL).
Array-CGH analyses were performed using the Agilent Human
Genome CGH Microarray Kit G3 400 (Agilent Technologies,
Palo Alto, USA) with 5.3 Kb overall median probe spacing.
Labeling and hybridization were performed following the proto-
cols provided by the manufacturer. Data analysis was performed
using the Agilent Genomic Workbench Lite Edition Software
6.5.0.18(2) with the following settings for aberration calling: ADM-
2 algorithm (threshold 6) with a moving average of 500 KB and
visual inspection of the log2 ratios. DNA sequence information
was according to the UCSC Genome Browser (http://genome.
ucsc.edu/; GRCh37/hg19, February 2009).
Expression analysis
For CNP radio-immunoassays, blood samples from the patient,
his parents and healthy volunteers were withdrawn in pre-chilled
tubes containing aprotinin. After centrifugation at 1.200 rpm for
10 min at 4uC, plasma was collected and stored at 280uC until
measurement. Plasma samples were purified on Sep-Pak C18
cartridges (Waters) and CNP content was determined using a RIA
kit (Phoenix Pharmaceuticals, Belmont, CA; RKU-012-03)
according to the manufacturer’s protocol. For analysis of CNP
Figure 5. Expression and biochemical results. A) CNP plasma
concentration in patient 2, his parents and three controls. The
concentration of the peptide was increased more than 4-fold in the
propositus compared to parents and unrelated controls (n = 3). B)
Analysis of NPPC expression by real-time PCR analysis in lymphoblasts
from patient and his parents. The expression of NPPC in the propositus
was remarkably higher compared to those of his father and mother.
doi:10.1371/journal.pone.0066048.g005
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and GAPDH mRNA expression in lymphoblast cells, total RNA
was isolated using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s protocol. Following DNAse treatment, first strand
cDNA was synthesized using the Advantage-RT-for-PCR kit
(Clontech). Expression of CNP and GAPDH mRNAs was
analyzed by real-time PCR (TaqManH gene expression master
mix; Applied Biosystems) using ABI 7900 HT device.
The following primers were used:
1. NPPC forward: 59-AGCGTGGGCTCGCCTT-39
2. NPPC reverse: 59-CTTGTTGGCTCCTTTGTATTTGC-39
3. NPPC probe: 59-6-FAM-TGCAAGAGCACCCCAACGCG-
TAMRA- 39
4. GAPDH forward: 59-CCACTCCTCCACCTTTGAC -39
5. GAPDH reverse: 59-ACCCTGTTGCTGTAGCCA -39
6. GAPDH probe: 59-6-FAM-TTGCCCTCAACGAC-
CACTTTGTC-TAMRA- 39
Reactions included 40 cycles at 96uC for 30 sec and 60uC for
1 min. Sample volume was 20 ml.
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